Get you up to speed: Health Canada approves drug that treats sleep apnea in adults with obesity
Zepbound has been approved in Canada as the only GLP-1 drug for treating sleep disorders that cause temporary breathing cessation due to upper airway blockage. This development addresses a significant gap in treatment options for affected patients.
Health Canada has confirmed that Zepbound is the sole GLP-1 medication authorised in Canada for the treatment of sleep apnea. The approval marks a significant development, as prior options for this condition were limited.
Health Canada has approved Zepbound as the sole GLP-1 medication for the treatment of obstructive sleep apnoea. Following this decision, further studies are planned to monitor its long-term effectiveness and safety in the Canadian market.
What remains unclear — It is not specified how Zepbound compares to other potential treatments for the sleep disorder.
Health Canada approves Zepbound for treating sleep apnea in adults with obesity
Zepbound the now the only GLP-1 drug in Canada approved for the sleep disorder that causes people to stop breathing temporarily because their upper airway is blocked.